SBC Medical Group Holdings (SBC) investor relations material

Business overview and financial performance

• Operates as a medical services organization supporting Japan's largest aesthetic medical group, providing centralized services for clinics to enable scalability and efficiency.

• As of June 2026, operates 287 locations (up 34 YoY), with 6.92 million annual customer visits (+10%), and year-to-date clinic revenue up 11%.

• Q2 2026 revenue reached $49 million (+13% YoY), adjusted EBITDA $20 million (+32%), and EBITDA margin 41%.

• Profit growth outpaced revenue growth, driven by higher management services revenue and revised service fees.

• Completed structural reforms in 2025, entering a phase of re-acceleration in growth.

Strategic initiatives and growth drivers

• Pursuing four growth strategies: multi-brand expansion in aesthetic dermatology, non-aesthetic healthcare growth, global expansion, and AI-driven cost and service improvements.

• Multi-brand strategy includes rebranding and launching new clinic formats to address diverse customer needs, including men's aesthetics.

• Non-aesthetic healthcare positioned as a second growth engine, with a dedicated team established and focus on M&A and operational improvements.

• Global expansion includes a minority stake in OrangeTwist (US) and asset-light partnerships in Southeast Asia, starting with Thailand.

• AI is leveraged for customer experience, clinic network growth, and operational efficiency, supporting recurring revenue and EPS growth.

AI and operational enhancements

• AI tools implemented in customer support, call centers, and personalized services, improving customer experience and enabling higher service fees.

• AI-driven enhancements expected to add JPY 15 million annually in service fees with minimal additional cost, boosting margins.

• Data-driven marketing and multi-branding strategies have led to increased customer visits and spending.

• AI supports efficient clinic expansion and knowledge sharing across the network.